US 12,214,002 B2
Compositions and methods for treating antibiotic resistance
Christopher Burton Ford, Swampscott, MA (US); Jessica Bryant, Cambridge, MA (US); and Edward J. O'Brien, Arlington, MA (US)
Assigned to Seres Therapeutics, Inc., Cambridge, MA (US)
Appl. No. 16/760,757
Filed by Seres Therapeutics, Inc., Cambridge, MA (US)
PCT Filed Oct. 30, 2018, PCT No. PCT/US2018/058279
§ 371(c)(1), (2) Date Apr. 30, 2020,
PCT Pub. No. WO2019/089643, PCT Pub. Date May 9, 2019.
Claims priority of provisional application 62/578,698, filed on Oct. 30, 2017.
Claims priority of provisional application 62/741,346, filed on Oct. 4, 2018.
Prior Publication US 2020/0353018 A1, Nov. 12, 2020
Int. Cl. A61K 35/742 (2015.01); A61P 31/04 (2006.01)
CPC A61K 35/742 (2013.01) [A61P 31/04 (2018.01)] 20 Claims
 
1. A method of reducing an abundance of at least one antibiotic-resistance gene in the microbiome of a mammalian subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition comprising a combination of bacteria, the combination comprising Blautia wexlerae and Anaerotruncus colihominis, wherein after the administration of the composition, the abundance of the at least one antibiotic-resistance gene in the microbiome of the subject is reduced as compared to a corresponding subject who did not receive the administration of the composition, wherein the at least one antibiotic-resistance gene is capable of conferring resistance to beta-lactam antibiotics and at least one additional antibiotic drug class, and wherein:
(a) the Blautia wexlerae comprises a 16S rDNA sequence that is at least 97% identical to the 16S rDNA sequence set forth in any one of SEQ ID NOs: 104-110 and 255; and
(b) the Anaerotruncus colihominis comprises a 16S rDNA sequence that is at least 97% identical to the 16S rDNA sequence set forth in any one of SEQ ID NOs: 89-92.